MediciNova,Inc. Logo

MediciNova,Inc.

Developing small-molecule drugs for neurology, respiratory, and liver diseases.

4875 | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
米国カリフォルニア州ラ・ホイヤ、スウィート300、エグゼクティブ・スクエア4275
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

MediciNova, Inc. is a biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for serious diseases with unmet medical needs. The company's primary development efforts are concentrated on neurology, respiratory, and liver diseases. Its pipeline includes candidates such as MN-221, targeting respiratory conditions like acute exacerbations of asthma and COPD, and MN-001 for fibrotic diseases, including liver fibrosis (NASH) and idiopathic pulmonary fibrosis (IPF).

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for MediciNova,Inc. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-09-12 07:44
Regulatory News Service
確認書
Japanese 8.4 KB
2025-09-12 07:43
Interim Report
半期報告書
Japanese 386.0 KB
2025-06-25 03:32
Regulatory News Service
臨時報告書
Japanese 16.6 KB
2025-06-10 06:52
Regulatory News Service
内部統制報告書
Japanese 51.3 KB
2025-06-10 06:51
Regulatory News Service
確認書
Japanese 12.9 KB
2025-06-10 06:50
Annual Report
有価証券報告書
Japanese 3.0 MB
2024-09-11 04:32
Regulatory News Service
確認書
Japanese 13.0 KB
2024-09-11 04:28
Interim Report
半期報告書
Japanese 436.9 KB
2024-06-17 09:06
Regulatory News Service
臨時報告書
Japanese 15.4 KB
2024-06-13 05:03
Regulatory News Service
確認書
Japanese 13.1 KB
2024-06-13 05:02
Quarterly Report
四半期報告書
Japanese 424.9 KB
2024-06-10 09:48
Regulatory News Service
内部統制報告書
Japanese 51.4 KB
2024-06-10 09:46
Annual Report
有価証券報告書
Japanese 3.3 MB
2024-06-10 09:46
Regulatory News Service
確認書
Japanese 12.9 KB
2023-12-12 06:01
Regulatory News Service
確認書
Japanese 13.1 KB

Automate Your Workflow. Get a real-time feed of all MediciNova,Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for MediciNova,Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
GNI  Group Ltd. Logo
Biopharma firm developing novel drugs for cancer and inflammatory diseases using genetics.
Japan 2160
Goodwill Pharma Plc Logo
Integrated pharma CDMO developing Rx/OTC meds, supplements & devices for CEE markets.
Hungary GWPH
Grifols S.A. Logo
Leading producer of plasma-derived medicines for patients with rare and chronic diseases.
Spain GRF
Grindeks Logo
Develops & manufactures pharmaceuticals for cardiovascular, CNS, cancer, and diabetes globally.
Latvia GRD1R
Guard Therapeutics International AB Logo
Clinical-stage biotech developing drugs to prevent acute kidney injury during open-heart surgery.
Sweden GUARD
Haleon PLC Logo
A global consumer healthcare leader providing trusted, science-backed OTC brands for everyday health.
United Kingdom HLN
Halychpharm Logo
A pharmaceutical manufacturer of finished medicines and plant-derived phytochemical substances.
Ukraine GFARM
Hansa Biopharma Logo
Develops antibody-cleaving enzymes to treat rare diseases and enable organ transplants.
Sweden HNSA
HEALIOS K.K. Logo
Develops iPS and somatic stem cell therapies for diseases like ARDS and cancer.
Japan 4593
Heartseed株式会社 Logo
Develops iPSC-derived cell therapies to regenerate heart tissue for heart failure.
Japan 219A

Talk to a Data Expert

Have a question? We'll get back to you promptly.